BERLIN: A new Covid-19 vaccination that has been created to neutralise two Omicron versions will begin to be distributed by the German biotechnology business BioNTech at the beginning of the following month.

According to DPA report, quoting Der Spiegel, BioNTech chief executive Ugur Sahin said, "We will be able to deliver very soon, maybe around the beginning of September."

In a recent announcement, the European Medicines Agency (EMA) said that it would review applications for vaccines developed by BioNTech-Pfizer and Moderna for the BA.1 variant of the virus. However, in Europe, this form is becoming less popular.

However, the research stated that it is still anticipated that the new vaccination will be more successful in neutralising the variations that are already in use.

A vaccine modified by BioNTech and its US partner Pfizer for the BA.4 and BA.5 strains that are now prevalent in Europe is being tested by the EMA.Sahin informed Der Spiegel that BioNTech had just finished submitting the final paperwork to the EMA. Then, he said, things may move swiftly here as well.

In the meantime, a recent study found that the Pfizer-BioNTech Covid-19 vaccine was 73% effective in defending kids between the ages of 6 months and 4 years during the period when the Omicron strain was extremely common.
On June 17, the US Food and Drug Administration authorised the vaccine Emergency Use Authorization for this age range.

Study finds Smoking also leads to thicker, weaker hearts

Pfizer's Covid vaccine 73-pc effective in kids under 5-yrs

Lancet study finds Smallpox vax against monkeypox may not be lasting